Pharma 2020: The vision

Which path will you take?

By 2020 the pharmaceutical market is anticipated to more than double to US$1.3 trillion, with the E7 countries — Brazil, China, India, Indonesia, Mexico, Russia and Turkey — accounting around for one fifth of global pharmaceutical sales. Further, incidence of chronic conditions in the developing world will increasingly resemble those of the developed world.

Pharma 2020: The vision: Which path will you take? indicates that the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough to produce the types of innovative treatments demanded by global markets. In order to make the most of these future growth opportunities, the industry must fundamentally change the way it operates.

Some of the major changes PwC anticipates for the industry are:

  • Health care will shift in focus from treatment to prevention.
  • Pharmaceutical companies will provide total health care packages.
  • The current linear phase research & development process will give way to in-life testing and live licensing, in collaboration with regulators and health care providers.
  • The traditional blockbuster sales model will disappear.
  • The supply chain function will become revenue generating as it becomes integral to the health care package and enables access to new channels.
  • More sophisticated direct-to-consumer distribution channels will diminish the role of wholesalers.

Contact us

Mike Swanick
Global Pharma and Life Sciences Leader, PwC US
Tel: +1 (267) 330 6060

Douglas Strang
Global & US Pharma/LS Advisory Leader, PwC US
Tel: +1 (267) 330 3045

Andrew Packman
Global Pharma/LS Tax Leader, PwC UK
Tel: +44 (0)189 552 2104

Peter Kartscher
Global Pharma/LS Assurance Leaser, PwC Israel
Tel: +972 3 795 4410

Follow us